Comments
Shares of Cipla Ltd fell as much as 3.5 per cent to Rs 500.25 on Thursday morning. The drugmaker posted a 6 per cent jump in June-quarter profit to Rs 478 crore ($67.48 million), missing estimates of Rs 496 crore.
Domestic trade generics business would collapse, while FY 20 domestic growth would likely fall to 4-5 per cent, Kotak Institutional Equites said.
Uncertainties remain around the trade generics ramp-up in India and the slowdown in the South Africa tender business, according to Nomura.
Jefferies expects margins to moderate from current levels even as revenues improve, led by mix and higher research and development. It has cut TP to Rs 520 from Rs 535 and retained a “hold” on the stock.
Around 2.6 million shares changed hands, versus the 30-day average of 1.6 million shares.
Up to last close, Cipla was down 0.23 per cent this year, while peer Lupin, which posted a 49 per cent rise in Q1 profit on Wednesday, fell 7.3 per cent ($1 = 70.8325 rupees).
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.